Abstract Objective To evaluate the clinical dosimetry characteristics of linear accelerator intensity-modulated radiation therapy (IMRT) for esophageal cancer at different pathological sites. Methods The clinical data of 132 patients with esophageal cancer admitted to Haian Traditional Chinese Medicine Hospital of Jiangsu Province from November 2019 to October 2021 were retrospectively analyzed, including 33 patients with cervical and upper, middle, and lower thoracic esophageal cancer. The difference of planned target dose, the dosimetric index of sketched organs at risk, machine hops, dose-validation pass rate, and treatment time of linear accelerator IMRT in patients with esophageal cancer at different sites was compared. Results The 2% of target volume exposure dose (D2), D50, D98, and mean dose (Dmean) in patients with upper and middle thoracic esophageal cancer were higher than those in cervical patients, and the treatment time was longer than that in cervical patients; target dose homogeneity index (HI) in patients with middle thoracic esophageal cancer was higher than that in cervical patients; the volume receiving a radiation dose of 25 Gy (V25), Dmean of the heart and V5, V20, V30 of both lungs in patients with upper, middle, and lower thoracic esophageal cancer were higher than those in cervical patients; the dose-validation pass rate in patients with upper and lower thoracic esophageal cancer were higher than those of cervical patients (P＜0.05). D2, HI, V25 of heart, Dmean of heart, and V5, V20, V30 of both lungs in patients middle thoracic esophageal cancer were higher than those in upper thoracic patients, and the dose-validation pass rate was lower than that in upper thoracic patients; the machine hops in patients with lower thoracic esophageal cancer were lower than those in upper thoracic patients, the treatment time was shorter than that in upper thoracic patients (P＜0.05). D2, D50, D98, Dmean, HI, and machine hops in patients with lower thoracic esophageal cancer were lower than those in middle thoracic patients, and V25, Dmean of heart, and dose-validation pass rate were higher than those in middle thoracic patients, and the treatment time was shorter than that in middle thoracic patients (P＜0.05). Conclusion The clinical dose of linear accelerator IMRT in different pathological sites of esophageal cancer is different, which should be paid attention to in clinic.
LU Dongyun YANG Jian SUN Jinyi ZHOU Jianjun YANG Jun▲. Clinical dosimetry evaluation of linear accelerator intensity-modulated radiation therapy for esophageal cancer at different sites[J]. 中国医药导报, 2023, 20(20): 125-128.
